Effectiveness of icatibant for treatment of hereditary angioedema attacks is not affected by body weight : findings from the Icatibant Outcome Survey, a cohort observational study. Caballero T et al. Clin Transl Allergy. 2018 Mar 23.
Specialist Advice Support for Management of Severe Hereditary Angioedema Attacks: A Multicenter Cluster-Randomized Controlled Trial. Javaud N et al. Ann Emerg Med. 2018 Mar.
Icatibant for ACE-inhibitor angioedema, an opportunity to treat the patients ? Javaud N et al. J Allergy Clin Immunol Pract. 2017 Nov – Dec.
Breakthrough attacks in patients with hereditary angioedema receiving long-term prophylaxis are responsive to icatibant: findings from the Icatibant Outcome Survey. Aberer W et al. Allergy Asthma Clin Immunol. 2017 Jul 5;13:3.
The Icatibant Outcome Survey: experience of hereditary angioedema management from six European countries. Caballero T et al. J Eur Acad Dermatol Venereol. 2017 Jul;31(7):1214-1222.
Normal PAI-2 level in French FXII-HAE patients. Marlu R et al. J Allergy Clin Immunol. 2017 May;139(5):1719-1720.
Hereditary angioedema with normal C1 inhibitor: clinical characteristics and treatment response with plasma-derived human C1 inhibitor concentrate (Berinert®) in a French cohort. Bouillet L et al. Eur J Dermatol. 2017 Apr 1;27(2):155-159.